Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE
- FDA approval represents Moderna's third approved product, expanding their commercial portfolio
- mNEXSPIKE showed 9.3% higher relative vaccine efficacy compared to existing Spikevax vaccine
- 13.5% higher relative vaccine efficacy in 65+ age group, targeting a key demographic
- Fewer local reactions reported compared to original vaccine while maintaining similar safety profile
- Product will be available for 2025-2026 respiratory season, providing near-term revenue potential
- Limited to specific population segments (65+ and high-risk 12-64 year olds)
- Faces competition from existing COVID-19 vaccines in the market
- Still requires regulatory approvals in other global markets
Insights
Moderna's new COVID vaccine approval strengthens revenue potential and diversifies portfolio with efficacy advantages over previous product.
Moderna has secured its third FDA-approved product with mNEXSPIKE (mRNA-1283), a next-generation COVID-19 vaccine. The approval covers adults 65+ and high-risk individuals aged 12-64, targeting populations most vulnerable to severe COVID outcomes. The approval is particularly significant as it diversifies Moderna's commercial portfolio beyond its original Spikevax and mRESVIA products.
The Phase 3 trial data is impressive, demonstrating
From a formulation perspective, mNEXSPIKE uses a 10 μg dose versus the original vaccine's 50 μg dose, representing an 80% reduction in active ingredient. This likely translates to manufacturing efficiency, potentially higher margins, and possibly fewer side effects. The safety profile supports this, showing fewer local reactions while maintaining comparable systemic reactions.
Timing is strategically important - with approval secured for the 2025-2026 respiratory virus season, Moderna positions itself to continue capturing COVID vaccine market share as the disease transitions to endemic status. With continuing annual mortality of 47,000 Americans, COVID remains a significant health threat requiring ongoing vaccination programs, particularly for high-risk populations covered by this approval.
mNEXSPIKE becomes Moderna's third FDA-approved product
CAMBRIDGE, MA / ACCESS Newswire / May 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mNEXSPIKE® (mRNA-1283), a new vaccine against COVID-19, for use in all adults 65 and older, as well as individuals aged 12-64 years with at least one or more underlying risk factor as defined by the Centers for Disease Control and Prevention (CDC).[1]
"The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from COVID-19," said Stéphane Bancel, Chief Executive Officer of Moderna. "COVID-19 remains a serious public health threat, with more than 47,000 Americans dying from the virus last year alone. We appreciate the FDA's timely review and thank the entire Moderna team for their hard work and continued commitment to public health."
The FDA's approval of mNEXSPIKE is based on results from a randomized, observer-blind, active-controlled Phase 3 clinical trial (ClinicalTrials.gov Identifier: NCT05815498), which enrolled approximately 11,400 participants aged 12 years and older. The primary efficacy objective in this study was to demonstrate the non-inferior vaccine efficacy against COVID-19 starting 14 days after mNEXSPIKE compared to that after the comparator vaccine, mRNA-1273 (Spikevax®), Moderna's original COVID-19 vaccine. Participants received either a 10 μg dose of mRNA-1283 or a 50 μg dose of mRNA-1273. mRNA-1283 showed a
In the Phase 3 trial, mRNA-1283 was found to have a similar safety profile to mRNA-1273, with fewer local reactions and comparable systemic reactions. The most commonly solicited side effects were injection site pain, fatigue, headache and myalgia.
Moderna expects to have mNEXSPIKE available for eligible populations in the U.S. for the 2025-2026 respiratory virus season, alongside Spikevax and mRESVIA®, the Company's approved respiratory syncytial virus (RSV) vaccine.
mRNA-1283 is under review with regulators in multiple markets around the world.
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
mNEXSPIKE®, mRESVIA® and Spikevax®are registered trademarks of Moderna.
INDICATION
mNEXSPIKE is a vaccine to protect against COVID-19. mNEXSPIKE is for people who have received a COVID-19 vaccine before and are:
• 65 years of age and older, or
• 12 years through 64 years of age at high risk for severe COVID-19.
Vaccination with mNEXSPIKE may not protect all people who receive the vaccine.
IMPORTANT SAFETY INFORMATION
You should not get mNEXSPIKE if you hada severe allergic reaction after a previous dose of either mNEXSPIKE, SPIKEVAX (COVID-19 Vaccine, mRNA), or any Moderna COVID-19 vaccine or to any ingredient in these vaccines.
What are the risks of mNEXSPIKE?
There is a very small chance that mNEXSPIKE could cause a severe allergic reaction. A severe allergic reaction would usually occur within a few minutes to 1 hour after getting a dose of mNEXSPIKE. For this reason, your healthcare provider may ask you to stay for a short time at the place where you received your vaccine. Signs of a severe allergic reaction can include:
Trouble breathing
Swelling of your face and throat
A fast heartbeat
A rash all over your body
Dizziness and weakness
Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received mRNA COVID-19 vaccines. Myocarditis and pericarditis following mRNA COVID-19 vaccines have occurred most commonly in males 12 years through 24 years of age. You should seek medical attention right away if you or your child has any of the following symptoms after receiving the vaccine, particularly during the 2 weeks after receiving a dose of the vaccine:
Chest pain
Shortness of breath
Feelings of having a fast-beating, fluttering, or pounding heart
Side effects that have been reported in clinical trials with mNEXSPIKE include:
Injection site reactions: pain, tenderness and swelling of the lymph nodes in the same arm of the injection, swelling (hardness), and redness.
General side effects: fatigue, headache, muscle pain, joint pain, chills, nausea, vomiting, and fever
Tell your vaccination provider about all of your medical conditions, including if you:
have any allergies
had a severe allergic reaction after receiving a previous dose of any COVID-19 vaccine
have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)
have a fever
have a bleeding disorder or are on a blood thinner
are immunocompromised or are on a medicine that affects your immune system
are pregnant or plan to become pregnant
are breastfeeding
have received any other COVID-19 vaccine
have ever fainted in association with an injection
These may not be all the possible side effects of mNEXSPIKE. Ask your healthcare provider about any side effects that concern you. You may report side effects to Vaccine Adverse Event Reporting System (VAERS) at 1-800-822-7967 or http://vaers.hhs.gov.
Please click for mNEXSPIKE Full Prescribing Information.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the efficacy, safety and tolerability of mNEXSPIKE; and the availability of Moderna's respiratory vaccines for the 2025-2026 season. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.
Moderna Contacts
Media:
Chris Ridley
Head of Global Media Relations
+1 617-800-3651
Chris.Ridley@modernatx.com
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com
[1] https://www.cdc.gov/covid/hcp/clinical-care/underlying-conditions.html
SOURCE: Moderna, Inc.
View the original press release on ACCESS Newswire
FAQ
What is Moderna's new FDA-approved COVID-19 vaccine called and who can receive it?
How does mNEXSPIKE's efficacy compare to Moderna's original COVID-19 vaccine?
What are the main side effects of Moderna's mNEXSPIKE vaccine?
When will Moderna's mNEXSPIKE be available in the United States?
How many products does Moderna now have FDA approved?
